In vivo treatment of tumor-bearing mice demonstrated that doxorubicin led to a significant increase in the number of CD4 + T cells, CD8+ T cells and NK cells and promoted expression of interferon γ (IFN-γ) and granzyme B (95). Here, CD8A is linked to neoplasm.